To better care for pregnant and postpartum mothers with ADHD, clinicians should understand the unique facets of ADHD in women, how symptoms change during pregnancy and the postpartum period, and how to help new parents make decisions around medication use and ADHD symptom management.
Postpartum SSRI treatment mitigated the negative associations between PPD and later maternal depression, partner relationship satisfaction, and child externalizing problems and ADHD symptoms up to 5 years after childbirth.
Dexmedetomidine, an α2-adrenergic receptor agonist, shows promise in preventing postpartum depression, reducing symptoms and improving sleep and pain control in women with prenatal depression.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
More study is needed regarding the safety of trazodone for the treatment of insomnia during pregnancy.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on August 15, 2023.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
